Profit

BSE Code: | NSE Code: | ISIN: | Sector:

NSE
631.00
Change Change %
1.20 0.19%

Updated:25 Sep, 2018, 13:54 PM IST

BSE
630.30
Change Change %
-0.55 -0.09%

Updated:25 Sep, 2018, 13:57 PM IST

Research Report Detail

Brokerage
Analyst
Report Date Call Price@Call Target Price
Stop Loss
Current Status Time Horizon
Nomura
N/A
02-08-2017 Buy 701.80 966.00
N/A
Closed Long (1Y)
02-08-2018

Nomura maintains buy on Glenmark Pharmaceuticals

On 1 August, Glenmark announced positive data from Phase IIa clinical trial for GBR 830. GBR 830 is an Ox40 antagonist biologic drug that can potentially be developed for treatment of autoimmune disorders. GBR 830 is the first in class and only OX40 antagonist under clinical development. The phase IIa study was a small signal study that measured efficacy endpoint on a small group of patients suffering from atopic dermatitis. The objective of the study was to establish proof of concept for the novel pathway. We believe there are multiple factors that make the asset attractive.

Top